Introduction The preparations of budesonide, Budenofalk and Entocort are licensed and recommended for the treatment of mild to moderate ileo-caecal Crohn’s disease (CD) (1). Budesonide is advantageous ...

Entocort EC (budesonide) is a Crohn's disease treatment for mild to moderate disease involving the ileum and/or the ascending colon. Entocort EC is a non-systemic glucocorticosteroid that is ...

Background—The use of corticosteroids in active Crohn’s disease often becomes limited by side effects. Budesonide is a potent corticosteroid with low systemic bioavailability due to an extensive first ...

Patients with Crohn's disease are faced with a lifetime of ... sequential ('step-up') approach with an initial treatment with budesonide or prednisone, followed by azathioprine if patients became ...

He had been provisionally diagnosed with Crohn's disease 6 months back and treated with budesonide and mesalazine. Investigations including C reactive protein, white cell count, coeliac antibodies, ...

We describe a case of a patient who developed an Addisonian crisis after inappropriate discontinuation of budesonide (a topical steroid used in Crohn's disease) treatment. Iatrogenic adrenal ...

Crohn’s Disease (CD) is a chronic inflammatory disorder ... Symptoms of mild to moderate disease are treated with mesalamine, budesonide, or systemic glucocorticoids. However, the benefit ...

Methods: A double blind, randomised, controlled trial over 12 weeks in 143 patients with active rheumatoid arthritis, comparing budesonide 3 mg daily, budesonide 9 mg daily, prednisolone 7.5 mg daily, ...